GSK’s New CEO Designate Walmsley Fortifies Volume Growth Strategy
Executive Summary
GSK’s new CEO will be Emma Walmsley, currently head of its Consumer Healthcare division. While some investors had wished for a company outsider with a ‘fresh pair of eyes’, GSK’s board decided to go for the best of both worlds: an insider with plenty of non-pharma experience.
You may also be interested in...
Jallal To Lead Immunocore, Building On Partnership She Forged At MedImmune
A key figure in AstraZeneca’s resurgence, Jallal now leaves to head up a clinical-stage firm. She’s been an outspoken advocate for greater gender equity in biopharma leadership.
From Pharma Insider To Payer: Witty To Lead United's Optum
Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.
From Witty To Walmsley – The Priorities For GSK's New CEO
It's Emma Walmsley's first week at the helm of GlaxoSmithKline. What can we expect in terms of her priorities?